# Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

> **NCT05329532** · PHASE1,PHASE2 · RECRUITING · sponsor: **Scancell Ltd** · enrollment: 168 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- Renal Cell Cancer
- High Grade Ovarian Serous Adenocarcinoma
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** Modi-1 Moditope
- **BIOLOGICAL:** Pembrolizumab
- **DEVICE:** MicronJet600™ microneedle device (NanoPass)

## Key facts

- **NCT ID:** NCT05329532
- **Lead sponsor:** Scancell Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-07
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05329532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05329532, "Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05329532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*